GlassScriptPhysician profile
Ajaz Afzal
NPI 1750341236
$2,515.06
in general payments reported to CMS, 2019-2025
35 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $506 · 2021: $117 · 2022: $367 · 2023: $654 · 2024: $359 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.78 | 2019-2025 | Linzess, Qulipta, Viberzi |
| Glaxosmithkline, LLC. | $313.62 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $232.13 | 2019-2025 | Breztri, Airsupra |
| Protega Pharmaceutials INC | $209.31 | 2022-2023 | Roxybond |
| Scilex Pharmaceuticals INC. | $197.75 | 2019-2023 | Ztlido |
| Novo Nordisk INC | $165.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $152.64 | 2019-2024 | |
| Amarin Pharma, INC. | $69.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $54.70 | 2020-2024 | Spravato |
| Lilly USA, LLC | $43.74 | 2023 | Mounjaro, Jardiance |
| Acadia Pharmaceuticals INC | $42.57 | 2022-2023 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $39.26 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $38.31 | 2023-2025 | Gvoke Hypopen |
| Gilead Sciences, INC. | $37.88 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.87 | 2025 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $34.12 | 2024-2025 | |
| Indivior INC. | $30.18 | 2020 | |
| Braeburn INC. | $26.73 | 2025 | Brixadi |
| Mylan Specialty L.P. | $26.22 | 2023 | Yupelri |
| Almatica Pharma LLC | $24.81 | 2023 | Loreev Xr |
| Horizon Therapeutics Plc | $21.94 | 2021 | |
| Axsome Therapeutics, INC. | $21.89 | 2025 | Symbravo |
| Orexo US, INC. | $21.46 | 2019 | |
| Merck Sharp & Dohme LLC | $21.27 | 2023 | Belsomra, Steglatro, Steglujan |
| Bayer Healthcare Pharmaceuticals INC. | $21.15 | 2024 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.81 | 2025 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $19.62 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.18 | 2023 | Nuzyra |
| Ardelyx, INC. | $17.87 | 2023 | Ibsrela |
| Astellas Pharma US INC | $16.97 | 2019 | |
| Amgen INC. | $15.20 | 2023 | Otezla, Repatha |
| Lundbeck LLC | $14.48 | 2025 | Rexulti |
| Organogenesis INC. | $14.21 | 2024 | |
| Strongbridge US INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajaz Afzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.